Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide

• US 5,571,533 A
• Filed: 05/09/1994
• Issued: 11/05/1996
• Est. Priority Date: 02/07/1992
• Status: Expired due to Fees

• Current Assignee: Recordati S.A. Chemical and Pharmaceutical Company
• Original Assignee: Recordati S.A. Chemical and Pharmaceutical Company
• Inventors: Lazzarini, Caterina, Santus, Giancarlo, Bottoni, Giuseppe
• Primary Examiner(s): Kulkosky, Peter F.
• Application Number:
  US08/240,033
• Time in Patent Office: 911 Days
• Field of Search: 424/78.04, 424/484, 424/469, 424/498
• US Class Current: 424/469
• CPC Class Codes: A61K 31/635 having a heterocyclic ring, e.g. sulfadiazine
• CPC Class Codes: A61K 9/1617 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds
• CPC Class Codes: A61K 9/5026 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/5047 Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/5084 Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs tablets containing such a mixture A61K9/2077

Abstract

Disclosed are controlled-release mucoadhesive pharmaceutical compositions for the oral administration of furosemide. This composition comprises a multiplicity of microgranules of lipophilic material which are coated with a mucoadhesive coating. This invention reduced or eliminates the diuresis peak and reduces inter-subject response variability which normally accompany conventional treatment with this drug.

Claims

1. An oral dosage form containing an effective amount of furosemide for inducing diuresis in a human and having both control-release and mucoadhesive properties, said dosage form comprising:

a) a multiplicity of controlled-release microgranules containing said furosemide and one or more granulation excipients having an overall Hydrophilic Lipophilic Balance (HLB) lower than 8;

said microgranules having substantially no mucoadhesive properties prior to coating with a mucoadhesive;

said granulation excipients being selected from the group consisting of saturated glycerides and polyglycolyzed glycerides;

b) a coating containing at least one mucoadhesive constituent, said coating having been applied to the surface of said microgranules to substantially completely envelop each microgranule, said coating having been applied in a manner so that it is non-swollen by water, the coating enveloping each microgranule being substantially detached from coatings enveloping other microgranules, and said coating ensuring adhesion of the coated microgranules to the mucous membrane of the gastrointestinal tract; and

c) extragranular excipients mixed with the mucoadhesive microgranules, facilitating non-aggregation and dispersion of the mucoadhesive microgranules over the mucous membrane of the gastrointestinal tract and detachment of the coating enveloping each microgranule from the coatings enveloping other microgranules.

2. A pharmaceutical composition according to claim 1, wherein the granulation excipients comprise hydrogenated castor-oil and mixtures of polyglycolyzed and polyoxyethylenated glycerides.

3. A composition according to claim 1, wherein the mucoadhesive polymer or polymers are chosen from a group consisting of carbomer, polycarbophil, hydroxypropylmethylcellulose, hydroxypropylcellulose and mixtures of at least two of the foregoing.

4. A composition according to claim 1, wherein the mucoadhesive coating comprises at least one mucoadhesive constituent and at least one non-mucoadhesive constituent, and the weight ratio between the at least one mucoadhesive constituent and the at least one non-mucoadhesive constituent is within the range from 20:

1 to 0.2;

1.

5. A composition according to claim 1, wherein the mucoadhesive coating comprises at least one mucoadhesive constituent and at least one non-mucoadhesive constituents, the weight ratio between the at least one mucoadhesive constituent and the at least one non-mucoadhesive constituent is within the range from 5:

1 to 0.5;

1.

6. A composition according to claim 1, wherein the weight ratio between the controlled-release units and the at least one mucoadhesive constituent of said coating is within the range between 5:

1 and 0.1;

1.

7. A composition according to claim 1, wherein the weight ratio between the controlled-release units and the at least one mucoadhesive constituent of said coating is within the range between 2.5:

1 and 0.25;

1.

8. A composition according to claim 1, wherein the mean geometric diameter of the microgranules coated with the mucoadhesive coating does not exceed 600 microns.

9. A composition according to claim 1 wherein the extragranular excipients comprise at least one hydrophobic substance delaying hydration of the mucoadhesive coating and at least one disintegrating substance promoting dispersion of the coated microgranules over the mucous membrane of the gastrointestinal tract.

10. A composition according to claim 9, wherein the hydrophobic substance is chosen from the group consisting of magnesium stearate, calcium stearate, talc, and combinations of at least two of the foregoing.

11. A composition according to claim 9, wherein the disintegrating substance is chosen from the group consisting of crosslinked polyvinylpyrrolidone, carboxymethyl starch, croscarmellose sodium, starch, and combinations of at least two of the foregoing.

12. A composition according to claim 7, wherein based on the total ingredients contained in the dosage form, the percentage by weight of the hydrophobic ingredient is within the range between 1 and 10% and that of the disintegrating ingredient is within the range between 2 and 20%.

13. A dosage form according to claim 1, wherein elements (a), (b) and (c) are contained in a hard gelatine capsule.

14. A process for preparing a pharmaceutical composition according to any one of claims 1-13, comprising the steps of:

a) granulating the active ingredient with one or more granulating excipients having an overall HLB lower than 8 to obtain controlled-release microgranules;

b) mixing the controlled-release microgranules with a material comprising at least one mucoadhesive constituent;

c) dry granulating said mixture;

d) crumbling said dry granulate; and

c) selecting granules of a desired size.

15. The process of claim 14, said mixing step taking place in the presence of a lubricant.

16. A method for increasing diuresis in a human subject in need of such treatment comprising administering to said subject an oral dosage form according to any one of claims 1-13.

17. A composition according to claim 1 wherein the granulation excipients comprise one or more polyethylene glycol monoesters or diesters of one or more fatty acids.

18. A composition according to claim 1 wherein the granulation excipients comprise products of alcoholysis of hydrogenated vegetable oils.

20. A composition according to claim 1 wherein the granulation excipient comprises one or more glycerol monoesters, diesters, or triesters of fatty acids.

21. A composition according to claim 17 wherein said fatty acids are selected from the group consisting of caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, and stearic acid.

22. A composition according to claim 20 wherein said fatty acids are selected from the group consisting of caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, and stearic acid.

23. A composition according to claim 1 wherein said granulation excipient comprises glyceryl monostearate.

24. A composition according to claim 1 wherein said granulation excipient comprises glyceryl monopalmitate stearate.

25. A composition according to claim 1 wherein said granulation excipient comprises glyceryl monomyristate.

26. A composition according to claim 1 wherein said granulation excipient comprises polyethyleneglycol monostearate.

27. A composition according to claim 1 wherein said granulation excipient comprises polyethyleneglycol palmitate stearate.

19. A composition according to claim I wherein the granulation excipients comprise products of esterification of saturated fatty acids.